Your browser doesn't support javascript.
loading
Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 128-132, 2015.
Article in Chinese | WPRIM | ID: wpr-248396
ABSTRACT
<p><b>OBJECTIVE</b>To compare the short-term efficacy and observe the tolerability and safety of recombinant human endostatin combined with induction chemotherapy followed by chemoradiotherapy for locally advanced nasopharyngeal carcinoma.</p><p><b>METHODS</b>Fifty-three patients with locally advanced nasopharyngeal carcinoma, who received recombinant human endostatin combined with induction chemotherapy followed by chemoradiotherapy, treated in our department from December 2011 to March 2013 were included in the study group of this study. Another 48 patients, who received induction chemotherapy followed by chemoradiotherapy alone in the same period, were chosen as a control group. The short-term outcome, overall survival (OS), progression-free survival (PFS), and acute side effects of the two groups were compared.</p><p><b>RESULTS</b>The complete remission rates of nasopharyngeal tumor in the study and control groups were 77.4% and 72.9%, respectively (P=0.154). The complete remission rates of patients with and without cervical lymph node metastasis were 75.5% and 62.6%, respectively, showing a significant difference (P=0.037). The 2-year OS, PFS, and DMFS rates for the study group were 82.3%, 77.2%, and 82.2%, respectively, versus 87.2%, 84.3% and 84.2% for the control group, showing a non-significant differences between the two groups (P=0.938, P=0.551, and P=0.725).</p><p><b>CONCLUSIONS</b>The short-term results of recombinant human endostatin (Endostar) combined with induction chemotherapy followed by concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma are slightly better than that of induction chemotherapy followed by concurrent chemoradiotherapy alone, with tolerable treatment-related toxicity and no more side effects.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Radiotherapy / Remission Induction / Carcinoma / Antineoplastic Combined Chemotherapy Protocols / Nasopharyngeal Neoplasms / Cisplatin / Disease-Free Survival / Endostatins / Therapeutic Uses / Drug Therapy Limits: Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2015 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Radiotherapy / Remission Induction / Carcinoma / Antineoplastic Combined Chemotherapy Protocols / Nasopharyngeal Neoplasms / Cisplatin / Disease-Free Survival / Endostatins / Therapeutic Uses / Drug Therapy Limits: Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2015 Type: Article